Alteration of the serum microbiome composition in cirrhotic patients with ascites.
The progression of cirrhosis is associated with alterations in the composition of the gut microbiome. To assess microbial translocation, we compared the serum microbial composition of patients with and without ascites and characterized the ascitic fluid microbiome using 16S rDNA high-throughput sequencing data. A complex and specific microbial community was detected in the serum and ascitic fluid of patients with cirrhosis but barely detectable in the serum of healthy controls. The serum microbiome of patients with ascites presented higher levels of lipopolysaccharide binding protein, a marker of microbial translocation, associated with higher diversity and relative abundance of Clostridiales and an unknown genus belonging to the Cyanobacteria phylum compared to patients without ascites. The composition of the fecal microbiome was also more altered in patients with than without ascites, confirming previous studies on fecal microbiome. We propose that alteration of the serum and fecal microbiome composition be considered indicators of cirrhosis progression.
Department of Gastroenterology, Vall d'Hebron Research Institute, Passeig Vall d'Hebron 119-129, Barcelona 08035, Spain.
Alba
A
Santiago
Department of Gastroenterology, Vall d'Hebron Research Institute, Passeig Vall d'Hebron 119-129, Barcelona 08035, Spain.
Marta
M
Pozuelo
Department of Gastroenterology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.|Centro de Investigaciòn Biomédica en Red en el Área temática de Enfermedades Hepáticas y Digestivas, CIBERehd, Instituto de Salud Carlos III, Madrid, Spain.
Maria
M
Poca
Department of Gastroenterology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.
Cristina
C
Gely
Department of Immunology, Institut de Recerca-IIB Sant Pau, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.
Juan Camilo
JC
Nieto
Department of Gastroenterology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.|Centro de Investigaciòn Biomédica en Red en el Área temática de Enfermedades Hepáticas y Digestivas, CIBERehd, Instituto de Salud Carlos III, Madrid, Spain.
Xavier
X
Torras
Department of Gastroenterology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.|Centro de Investigaciòn Biomédica en Red en el Área temática de Enfermedades Hepáticas y Digestivas, CIBERehd, Instituto de Salud Carlos III, Madrid, Spain.|Escola Universitària d'Infermeria EUI-Sant Pau, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.
Eva
E
Román
Department of Gastroenterology, Vall d'Hebron Research Institute, Passeig Vall d'Hebron 119-129, Barcelona 08035, Spain.
David
D
Campos
Department of Gastroenterology, Vall d'Hebron Research Institute, Passeig Vall d'Hebron 119-129, Barcelona 08035, Spain.
Guillaume
G
Sarrabayrouse
Department of Immunology, Institut de Recerca-IIB Sant Pau, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.
Silvia
S
Vidal
Department of Gastroenterology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.
Edilmar
E
Alvarado-Tapias
Department of Gastroenterology, Vall d'Hebron Research Institute, Passeig Vall d'Hebron 119-129, Barcelona 08035, Spain.|Centro de Investigaciòn Biomédica en Red en el Área temática de Enfermedades Hepáticas y Digestivas, CIBERehd, Instituto de Salud Carlos III, Madrid, Spain.
Francisco
F
Guarner
Department of Gastroenterology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.|Centro de Investigaciòn Biomédica en Red en el Área temática de Enfermedades Hepáticas y Digestivas, CIBERehd, Instituto de Salud Carlos III, Madrid, Spain.
German
G
Soriano
Department of Gastroenterology, Vall d'Hebron Research Institute, Passeig Vall d'Hebron 119-129, Barcelona 08035, Spain.|Centro de Investigaciòn Biomédica en Red en el Área temática de Enfermedades Hepáticas y Digestivas, CIBERehd, Instituto de Salud Carlos III, Madrid, Spain.
Chaysavanh
C
Manichanh
Department of Gastroenterology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.|Centro de Investigaciòn Biomédica en Red en el Área temática de Enfermedades Hepáticas y Digestivas, CIBERehd, Instituto de Salud Carlos III, Madrid, Spain.
Carlos
C
Guarner
D000209:Acute-Phase Proteins; D001202:Ascitic Fluid / Q000382:microbiology*; D001419:Bacteria / Q000145:classification* / Q000235:genetics; D002352:Carrier Proteins / Q000097:blood; D018450:Disease Progression; D005243:Feces / Q000382:microbiology*; D000069196:Gastrointestinal Microbiome; D059014:High-Throughput Nucleotide Sequencing; D006801:Humans; D008103:Liver Cirrhosis / Q000097:blood / Q000382:microbiology*; D008562:Membrane Glycoproteins / Q000097:blood; D010802:Phylogeny; D012336:RNA, Ribosomal, 16S / Q000235:genetics; D017422:Sequence Analysis, DNA; D044967:Serum / Q000382:microbiology*; D000099231:Lipopolysaccharide-Binding Protein
D000209:Acute-Phase Proteins; D002352:Carrier Proteins; D008562:Membrane Glycoproteins; D012336:RNA, Ribosomal, 16S; D000099231:Lipopolysaccharide-Binding Protein